Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Allergan eye implant

Allergan’s Ozurdex eye implant to treat macular oedema has been approved for use by the UK’s NHS in draft guidance from the National Institute for Health and Clinical Excellence

Allergan's Ozurdex (dexamethasone) eye implant to treat macular oedema has been approved for use by the UK's NHS in draft guidance from the National Institute for Health and Clinical Excellence (NICE).

The implant is approved in patients with macular oedema following central retinal vein occlusion (CRVO) or following branch retinal vein occlusion (BRVO) when treatment with laser photocoagulation has not been beneficial or is not suitable.

RVO is the blockage of a blood vessel in the retina so blood cannot drain out. This can lead to damage of an individual's eyesight.

Ozurdex works by suppressing inflammation in the eye, and is injected every six months.

Final guidance is due to be published in July 2011, with registered stakeholders able to appeal against the draft recommendations.

The announcement follows the news that Novartis' wet age-related macular degeneration treatment Lucentis (ranibizumab injection) has been approved for a new indication of vision loss due to macular oedema following RVO by the European Commission.

Ozurdex was approved by the European Medicines Agency (EMA) in 2010 as the first treatment authorised in Europe for the treatment for its current indication.

7th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics